JP2020527152A5 - - Google Patents

Download PDF

Info

Publication number
JP2020527152A5
JP2020527152A5 JP2020502415A JP2020502415A JP2020527152A5 JP 2020527152 A5 JP2020527152 A5 JP 2020527152A5 JP 2020502415 A JP2020502415 A JP 2020502415A JP 2020502415 A JP2020502415 A JP 2020502415A JP 2020527152 A5 JP2020527152 A5 JP 2020527152A5
Authority
JP
Japan
Prior art keywords
variable region
chain variable
seq
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020502415A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527152A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/069460 external-priority patent/WO2019016247A2/en
Publication of JP2020527152A publication Critical patent/JP2020527152A/ja
Publication of JP2020527152A5 publication Critical patent/JP2020527152A5/ja
Pending legal-status Critical Current

Links

JP2020502415A 2017-07-20 2018-07-18 治療のための薬剤、使用及び方法 Pending JP2020527152A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201700419 2017-07-20
DKPA201700419 2017-07-20
PCT/EP2018/069460 WO2019016247A2 (en) 2017-07-20 2018-07-18 AGENTS, USES AND METHODS OF TREATMENT

Publications (2)

Publication Number Publication Date
JP2020527152A JP2020527152A (ja) 2020-09-03
JP2020527152A5 true JP2020527152A5 (US20070167479A1-20070719-C00034.png) 2021-07-29

Family

ID=63113476

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020502415A Pending JP2020527152A (ja) 2017-07-20 2018-07-18 治療のための薬剤、使用及び方法

Country Status (25)

Country Link
US (2) US10894833B2 (US20070167479A1-20070719-C00034.png)
EP (1) EP3655438A2 (US20070167479A1-20070719-C00034.png)
JP (1) JP2020527152A (US20070167479A1-20070719-C00034.png)
KR (1) KR20200031610A (US20070167479A1-20070719-C00034.png)
CN (1) CN110945029A (US20070167479A1-20070719-C00034.png)
AR (1) AR112563A1 (US20070167479A1-20070719-C00034.png)
AU (1) AU2018303175A1 (US20070167479A1-20070719-C00034.png)
BR (1) BR112019005428A2 (US20070167479A1-20070719-C00034.png)
CA (1) CA3069391A1 (US20070167479A1-20070719-C00034.png)
CL (1) CL2020000070A1 (US20070167479A1-20070719-C00034.png)
CO (1) CO2019014090A2 (US20070167479A1-20070719-C00034.png)
CR (1) CR20200027A (US20070167479A1-20070719-C00034.png)
DO (1) DOP2020000006A (US20070167479A1-20070719-C00034.png)
EA (1) EA201992688A1 (US20070167479A1-20070719-C00034.png)
EC (1) ECSP20002935A (US20070167479A1-20070719-C00034.png)
IL (1) IL271728B2 (US20070167479A1-20070719-C00034.png)
JO (1) JOP20200007A1 (US20070167479A1-20070719-C00034.png)
MA (1) MA49633A (US20070167479A1-20070719-C00034.png)
NI (1) NI202000005A (US20070167479A1-20070719-C00034.png)
PE (1) PE20210467A1 (US20070167479A1-20070719-C00034.png)
PH (1) PH12019502869A1 (US20070167479A1-20070719-C00034.png)
RU (1) RU2019140933A (US20070167479A1-20070719-C00034.png)
SG (1) SG11201912228WA (US20070167479A1-20070719-C00034.png)
TW (1) TW201908342A (US20070167479A1-20070719-C00034.png)
WO (1) WO2019016247A2 (US20070167479A1-20070719-C00034.png)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3280441T (pt) 2015-04-07 2021-11-30 Alector Llc Anticorpos anti-sortilina e métodos para a sua utilização
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
SI3618928T1 (sl) 2018-07-13 2023-04-28 Alector Llc Protitelesa proti sortilinu in postopki za uporabo le-teh
CN113645996B (zh) * 2019-02-01 2024-04-02 新石生物制药有限公司 抗claudin 18抗体及其使用方法
WO2023247754A1 (en) 2022-06-23 2023-12-28 Draupnir Bio Aps Bifunctional molecules that selectively induce degradation of extracellular targets in lysosomes

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JP3070763B2 (ja) 1989-08-09 2000-07-31 ロメッド インコーポレイティド テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5101990A (en) 1990-03-23 1992-04-07 Continental Pet Technologies, Inc. Stretch blow molded oblong or oval container
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
DK0804070T3 (da) 1993-03-09 2000-08-07 Genzyme Corp Fremgangsmåde til isolering af proteiner fra mælk
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
CA2361421A1 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
JP2003516718A (ja) 1999-07-29 2003-05-20 メダレックス インク HER2/neuに対するヒトモノクローナル抗体
MXPA02001911A (es) 1999-08-24 2003-07-21 Medarex Inc Anticuerpos ctla-4 humanos y sus usos.
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
EP1539233B1 (en) 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
US8066997B2 (en) 2002-12-20 2011-11-29 Anders Nykjaer Modulation of activity of neurotrophins
EP1973576B1 (en) 2005-11-28 2019-05-15 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
WO2008076262A2 (en) 2006-12-15 2008-06-26 Merck & Co., Inc. Receptor for amyloid beta and uses thereof
PL3225251T3 (pl) 2006-12-21 2020-06-29 H. Lundbeck A/S Modulacja aktywności proneurotrofin
EP2185692A4 (en) 2007-08-10 2012-05-02 Medarex Inc HCO32 AND HCO27 AND RELATED EXAMPLES
US20100324127A1 (en) * 2008-01-16 2010-12-23 Kay Denis G Treating neurodegenerative diseases with progranulin
EP2274327B1 (en) 2008-04-27 2019-03-27 H. Lundbeck A/S Crystal structure of human sortilin and uses thereof for identifying ligands to sortilin
WO2009154995A2 (en) * 2008-05-27 2009-12-23 Kyowa Hakko Kirin Co., Ltd. Interleukin 10 receptor (il-10r) antibodies and methods of use
US20120039865A1 (en) 2008-08-19 2012-02-16 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
US8703125B2 (en) 2008-12-19 2014-04-22 H. Lundbeck A/S Modulation of the Vps10p-domain receptor family for the treatment of mental and behavioural disorders
US9822366B2 (en) 2012-11-02 2017-11-21 The Brigham And Women's Hospital, Inc. Sortilin 1 is a novel inducer of vascular calcification
WO2015143300A1 (en) * 2014-03-21 2015-09-24 The Board Of Regents Of The University Of Texas System Isoxazole treatments for frontotemporal dementia
US10428158B2 (en) * 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
PT3280441T (pt) * 2015-04-07 2021-11-30 Alector Llc Anticorpos anti-sortilina e métodos para a sua utilização
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
PE20191741A1 (es) * 2017-04-05 2019-12-12 Symphogen As Terapias combinadas dirigidas a pd-1, tim-3, y lag-3
SI3618928T1 (sl) * 2018-07-13 2023-04-28 Alector Llc Protitelesa proti sortilinu in postopki za uporabo le-teh
CN113151432A (zh) * 2020-04-14 2021-07-23 郁金泰 神经退行性疾病检测和治疗的新靶标

Similar Documents

Publication Publication Date Title
US11136398B2 (en) PDGF receptor beta binding polypeptides
JP2020527152A5 (US20070167479A1-20070719-C00034.png)
JP7254699B2 (ja) 抗bcma重鎖のみ抗体
TWI545133B (zh) 抗-il-23抗體
RU2019140933A (ru) Средства, пути применения и способы лечения
JP6779012B2 (ja) ブラジキニンb1受容体リガンドに対する抗体
JP2016533335A5 (US20070167479A1-20070719-C00034.png)
JP2020002172A5 (US20070167479A1-20070719-C00034.png)
JP2018529635A5 (US20070167479A1-20070719-C00034.png)
TW201406391A (zh) 抗-il-23抗體
US20240075133A1 (en) Methods and compositions for reduction of immunogenicity
JP2009533367A5 (US20070167479A1-20070719-C00034.png)
JP2013508292A5 (US20070167479A1-20070719-C00034.png)
TW202204413A (zh) 用於血腦障壁遞送之組成物及方法
AU2017292752A1 (en) Antibodies with low immunogenicity and uses thereof
RU2018100824A (ru) Антитела, которые связываются с сортилином и подавляют связывание програнулина
US20240101674A1 (en) Pd1 and vegfr2 dual-binding agents
JP2023520811A (ja) 抗cd98抗体およびその使用
JP2020505350A5 (US20070167479A1-20070719-C00034.png)
TW202114734A (zh) Il-17拮抗劑治療自身免疫疾病的方法
US20220041694A1 (en) Sars-cov-2 antibodies for treatment and prevention of covid-19
US20230406942A1 (en) Igf1r antibodies
TW202342095A (zh) 用於治療和預防covid—19之組成物
TW202342516A (zh) 識別分選蛋白的抗體
WO2024112561A1 (en) Methods for the treatment of myasthenia gravis